Diagnostic tools and innovative therapies improve patient...(r carcinoma or malignant yielded a 29...),Health

Date:8/2/2009

r carcinoma" or "malignant" yielded a 29.5 percent sensitivity rate, the ability of the test to predict the presence of lung cancer. If the RASSF1A gene alone was used for methyl group presence, the sensitivity of the test was 41 percent. The combination of both increases the sensitivity to 54 percent.

For a combination of the selected three genes for methyl groups, however, the sensitivity increased to 61 percent, supporting the use of methylation analysis in sputum as a way to potentially diagnose lung cancer.

"This test could offer a novel, non-invasive and accurate way to test for the presence of lung cancer, possibly improving the chances of an early diagnosis and a better prognosis," says Dr. Thunnissen.

Dr. Thunnissen will present this study on Tuesday, August, 4, 2009 at 1:20 pm PT in Moscone West, Room 2020-2022, Level 2.

'/>"/>

Contact: Liz Wulderk lwulderk@spectrumscience.com 443-506-1931 International Association for the Study of Lung Cancer Source:Eurekalert

0 GOOD

Page: 1 2 3 4 5 6
Related medicine news :

1. Addario Lung Cancer Medical Institute Announces Diagnostic Screening and Clinical Research Collaborations With Response Genetics, Inc.
2. Growth in Personalized Medicine to Drive Alliances Between Diagnostics and Pharmaceutical Industries, According to PricewaterhouseCoopers
3. New Diagnostic Biomarker Test Shows Promise in Monitoring Ovarian Cancer
4. Roche Cardiac 200 Offers Rapid Cardiac Diagnostics for the Point of Care
5. Abbott Introduces Molecular Diagnostic System Intended for Broad Identification of Infectious Agents
6. Ortho Clinical Diagnostics Launches 24-Hour Remote Monitoring Center
7. FDA Approves VITROS(R) Anti-HCV Assay for Use On VITROS 5600(R) Integrated and VITROS 3600(R) Immunodiagnostic Systems
8. Quest Diagnostics Reports Strong Performance in Second Quarter 2009
9. Quest Diagnostics MedPlus Subsidiary Enables New York Clinical Information Exchange (NYCLIX) to Share Meaningful Data and Enhance Patient Care
10. Enigma Diagnostics Announces Signing of Patent Licenses With Roche Molecular Systems, Inc.
11. New Medical Imaging Organization Launched to Represent Industry Personnel and Diagnostic Clinics